Loading...
XKRX004720
Market cap55mUSD
Jan 10, Last price  
4,525.00KRW
1D
-1.74%
1Q
-5.53%
Jan 2017
-73.77%
Name

PharmGen Science Inc

Chart & Performance

D1W1MN
XKRX:004720 chart
P/E
14.35
P/S
0.49
EPS
315.39
Div Yield, %
0.00%
Shrs. gr., 5y
12.66%
Rev. gr., 5y
13.36%
Revenues
166.78b
+10.50%
78,559,320,00077,680,145,00048,740,944,00043,926,893,00027,911,913,08030,291,620,67038,971,052,56044,203,012,42060,405,445,20071,545,613,18079,894,496,57089,101,640,00095,137,668,55096,614,310,440109,866,066,810150,930,715,370166,778,825,650
Net income
5.73b
-91.83%
-221,835,000-11,315,404,000-1,946,753,000-2,765,635,000-8,823,738,000-5,231,609,800-3,698,557,000-4,583,680,0002,067,281,0003,452,135,9304,319,900,3104,467,984,120235,995,6009,222,178,37032,465,959,37070,059,662,0405,727,238,830
CFO
5.44b
P
-5,533,603,0003,823,582,000-14,702,708,000628,491,0002,893,279,980-3,975,637,310-4,204,856,380-2,016,894,3203,621,572,7407,754,655,7901,837,763,3804,215,582,0902,523,396,0002,675,611,6407,784,092,730-1,286,177,4105,438,941,449

Profile

PharmGen Science, Inc. engages in the research and development, production, and sale of pharmaceutical products in South Korea. It offers prescription drugs, OTC drugs, health food, and cosmetics. It offers its products in the form of tablet, hard capsule, granule and ointment, syrups, and suspension forms. The company was formerly known as Wooridul Pharmaceutical Limited and changed its name to PharmGen Science, Inc. PharmGen Science, Inc. was founded in 1961 and is headquartered in Hwaseong, South Korea.
URL
http://www.wooridulpharm.com/
IPO date
Jun 15, 1990
Employees
Domiciled in
KR
Incorporated in
KR

Valuation

Title
KRW in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
166,778,826
10.50%
150,930,715
37.38%
Cost of revenue
137,560,042
120,337,927
Unusual Expense (Income)
NOPBT
29,218,783
30,592,788
NOPBT Margin
17.52%
20.27%
Operating Taxes
2,265,007
19,902,113
Tax Rate
7.75%
65.05%
NOPAT
26,953,777
10,690,675
Net income
5,727,239
-91.83%
70,059,662
115.79%
Dividends
Dividend yield
Proceeds from repurchase of equity
(12,407)
(5,767)
BB yield
0.01%
0.00%
Debt
Debt current
37,431,144
39,001,393
Long-term debt
1,475,532
1,426,194
Deferred revenue
4
Other long-term liabilities
14,980,866
13,413,777
Net debt
(180,534,194)
(166,187,122)
Cash flow
Cash from operating activities
5,438,941
(1,286,177)
CAPEX
(2,265,915)
(11,956,258)
Cash from investing activities
3,260,040
(15,284,385)
Cash from financing activities
8,851,958
2,269,033
FCF
16,539,395
1,178,892
Balance
Cash
37,437,384
19,885,875
Long term investments
182,003,486
186,728,833
Excess cash
211,101,929
199,068,172
Stockholders' equity
139,084,030
135,332,943
Invested Capital
142,071,627
122,626,320
ROIC
20.37%
8.64%
ROCE
9.42%
10.69%
EV
Common stock shares outstanding
20,796
21,591
Price
6,200.00
-7.19%
6,680.00
-36.38%
Market cap
128,933,724
-10.60%
144,228,541
-26.14%
EV
(51,610,577)
(21,967,651)
EBITDA
33,465,510
33,963,918
EV/EBITDA
Interest
4,263,984
3,508,941
Interest/NOPBT
14.59%
11.47%